A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Desoximetasone (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 03 May 2017 Planned End Date changed from 1 Apr 2017 to 1 May 2017.
- 03 May 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.